Lauri Welch, NP
Nurse Practitioner · North Chelmsford, MANPI 1972625788
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,420 of the $109,584 with a category attached, or 70.6%. 32 manufacturers reported payments, led by Gilead at 33.7% of the total. 2025 is the largest year on record at $46,710, 3.6 times the $12,874 reported in 2021. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 540 payments — averaging $202.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$37K
- Madrigal Pharmaceuticals$36K
- AbbVie$25K
- Phathom Pharmaceuticals, Inc.$7K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$926
- plus $3K from 26 others
What the payments were for
- Consulting fees$6,8056%
- Speaking & faculty fees$77,42071%
- Travel & lodging$11,46610%
- Food & beverage$13,75213%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 107 | $36,933 |
| Madrigal Pharmaceuticals | 68 | $36,085 |
| AbbVie | 128 | $24,581 |
| Phathom Pharmaceuticals, Inc. | 24 | $6,898 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $1,068 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $926 |
| Johnson & Johnson | 31 | $681 |
| Lilly USA, LLC | 10 | $325 |
| Bristol Myers Squibb | 12 | $304 |
| Pfizer | 9 | $191 |
| Ardelyx, Inc. | 8 | $167 |
| Ironwood Pharmaceuticals, Inc | 6 | $163 |
| QOL Medical, LLC | 5 | $142 |
| Sanofi | 4 | $113 |
| Ferring Pharmaceuticals Inc. | 4 | $105 |
| Regeneron Healthcare Solutions, Inc. | 5 | $104 |
| Intercept Pharmaceuticals, Inc. | 4 | $103 |
| Neuraxis, Inc. | 1 | $88 |
| Nestle Healthcare Nutrition Inc. | 4 | $77 |
| Celltrion USA Inc. | 4 | $72 |
| Fresenius Kabi USA, LLC | 2 | $63 |
| Boehringer Ingelheim | 2 | $60 |
| Ipsen Biopharmaceuticals, Inc | 2 | $55 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| Braintree Laboratories, Inc. | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Novo Nordisk | 2 | $43 |
| Laborie Medical Technologies Corp. | 1 | $37 |
| Apollo Endosurgery US Inc | 1 | $18 |
| Amgen | 1 | $15 |
| Merck | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,584 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $155,064 |
| XifaxanRifaximin | 18 | $66,823 |
| RezdiffraResmetirom | 11 | $55,718 |
| LinzessLinaclotide | 25 | $20,746 |
| OzempicSemaglutide | 18 | $17,505 |
| MounjaroTirzepatide | 14 | $15,499 |
| TrulancePlecanatide | 13 | $7,088 |
| Tenofovir Disoproxil Fumarate | 11 | $4,363 |
| Omeprazole | 121 | $2,179 |
| Pantoprazole Sodium | 67 | $1,022 |
| Dicyclomine Hcl | 50 | $955 |
| Esomeprazole Magnesium | 30 | $770 |
| Famotidine | 71 | $761 |
| Lactulose | 13 | $303 |
| Metoclopramide Hcl | 36 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $24,581 | $175,81057 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,068 | $73,91131 claims |
| Madrigal PharmaceuticalsRezdiffra | $36,085 | $55,71811 claims |
| Novo NordiskOzempic | $43 | $17,50518 claims |
| Lilly USA, LLCMounjaro | $325 | $15,49914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in North Chelmsford
- Kristen McFaddenNorth Chelmsford$8K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
- Lauren BurkeBoston$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.